CDEK
← All drugs Report issue

acyline

Small moleculeexperimental

Acyline is a gonadotropin-releasing hormone analogue and gonadotropin-releasing hormone antagonist which was never marketed. It has been shown to suppress gonadotropin and testosterone levels in men. Acyline is a peptide and under normal circumstances is not orally active. For this reason, it has instead been administered by subcutaneous injection. — Wikipedia

Clinical trial activity

16 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
10
Phase 2
9
Phase 3
1
Phase 4
0

Earliest trial started Oct 1, 2002 (NCT00470990)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(=O)Nc1ccc(C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](Cc2cccnc2)NC(=O)[C@@H](Cc2ccc(Cl)cc2)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(C)=O)C(=O)N[C@H](Cc2ccc(NC(C)=O)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@H](C)C(N)=O)cc1
Mol. weight
1533.24 g/mol
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • acycline
  • acyline
  • acyline
  • acyline

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02147964Phase 2Jan 1, 2017University of Washington
NCT02758431N/AFeb 1, 2016University of Colorado, Denver
NCT01686828Phase 1/Phase 2 (Phase 2)Jun 1, 2013University of Washington
NCT01327495Phase 2/Phase 3 (Phase 3)Oct 1, 2011National Institute on Aging (NIA), National Institutes of Health (NIH), University of Washington
NCT01215292Phase 1/Phase 2 (Phase 2)Jan 1, 2011National Institutes of Health (NIH), University of Washington
NCT01167829Phase 1Jul 1, 2010GlaxoSmithKline, University of Washington
NCT00842751Phase 2Jul 1, 2009National Institutes of Health (NIH), University of Washington
NCT00839319Phase 1/Phase 2 (Phase 2)Mar 1, 2009National Institutes of Health (NIH), University of Washington
NCT00729859Phase 2Dec 1, 2008National Institutes of Health (NIH), University of Washington
NCT00663793Phase 1Oct 1, 2008National Institutes of Health (NIH), University of Washington
NCT00603187Phase 1/Phase 2 (Phase 2)Jan 1, 2008Merrion Pharmaceuticals, LLC, University of Washington
NCT00471185Phase 1Jun 1, 2007Merrion Pharmaceuticals, LLC, University of Washington
NCT00156650Phase 1/Phase 2 (Phase 2)Dec 1, 2004National Institutes of Health (NIH), University of Washington
NCT00161486Phase 1Jul 1, 2004National Institutes of Health (NIH), University of Washington
NCT00161447Phase 1/Phase 2 (Phase 2)May 1, 2004CONRAD, National Institutes of Health (NIH), University of Washington
NCT00470990N/AOct 1, 2002American Diabetes Association, Harvard University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Showing 16 of 16 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of WashingtonAcademic/Hospital141432004
National Institutes of Health (NIH)Government9032004
Merrion Pharmaceuticals, LLCFor profit2022007
American Diabetes AssociationAcademic/Hospital1012002
CONRADFor profit1012004
GlaxoSmithKlineFor profit1012010
Harvard UniversityAcademic/Hospital1012002
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government1112002
National Institute on Aging (NIA)Government1012011
University of Colorado, DenverAcademic/Hospital1112016
10 organizations
Page 1 / 1